Attached files
file | filename |
---|---|
EX-32.1 - EXHIBIT 32.1 - SELLAS Life Sciences Group, Inc. | gale-20161231xex321.htm |
EX-31.1 - EXHIBIT 31.1 - SELLAS Life Sciences Group, Inc. | gale-20161231xex311.htm |
EX-21.1 - EXHIBIT 21.1 - SELLAS Life Sciences Group, Inc. | gale-20161231xex211.htm |
EX-4.1 - EXHIBIT 4.1 - SELLAS Life Sciences Group, Inc. | rxipc0211916.htm |
EX-3.3 - EXHIBIT 3.3 - SELLAS Life Sciences Group, Inc. | gale-20161231xex34.htm |
EX-3.1 - EXHIBIT 3.1 - SELLAS Life Sciences Group, Inc. | gale-20161231xex31.htm |
10-K - 10-K - SELLAS Life Sciences Group, Inc. | gale-20161231x10xk.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-188847, 333-188849, 333-195260, 333-199517, 333-208330, 333-208331, 333-212674, 333-213908, 333-213493, and 333-213908) and Form S-8 (Nos. 333-151154, 333-153847, 333-175763, 333-174819, 333-182578, 333-183300, 333-190540, 333-210833, and 333-213248) of our report dated March 15, 2017, relating to the consolidated financial statements of Galena Biopharma, Inc., and the effectiveness of internal control over financial reporting of Galena Biopharma, Inc., appearing in this Annual Report on Form 10-K for the year ended December 31, 2016.
/s/ Moss Adams
San Francisco, CA
March 15, 2017